Clearmind Medicine, Yissum Expand Collaboration With Submission Of International Patent Application For Generation 3.0 Psychedelic Compounds To Treat Mental Disorders
Portfolio Pulse from Benzinga Newsdesk
Clearmind Medicine Inc. (NASDAQ:CMND) has submitted an international patent application for generation 3.0 psychedelic compounds to treat mental disorders, in collaboration with Yissum Research Development Company of the Hebrew University of Jerusalem.
August 16, 2024 | 8:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Clearmind Medicine Inc. has submitted an international patent application for new psychedelic compounds to treat mental disorders, developed in collaboration with Yissum.
The submission of a patent application for new psychedelic compounds indicates progress in Clearmind's R&D efforts and potential future revenue streams. This development is likely to positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100